Lemtrada Sometimes Works Well But Patients Were Only Recently Warned About The Dangers of The Drug

Lemtrada Stroke Lawsuit News

Other Lemtrada side effects are equally as profound and include causing immediate death

Tuesday, October 6, 2020 - A recent Lemtrada study was mixed; reporting that on the one hand, Lemtrada showed promise in being able to control the number of brain lesions for patients with relapse-remitting multiple sclerosis (RRMS). In the study released on September 11, 2020, researchers concluded, "Alemtuzumab (Lemtrada) slowed brain atrophy over 6 years in patients without relapse and MRI disease activity." Scientists at Sanofi Genzyme, the maker of Lemtrada, conducted the study, and presented it to the 8th Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) - European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Meeting from 11-13 September 2020, according to WFM.com. Lemtrada attorneys offer a free consultation without obligation to file a lawsuit claim.

People who take Lemtrada do so only if their disease is highly active and rapidly worsening. Lemtrada should only be administered after all other drugs, disease-modifying therapies (DMTs), have failed and under the strict supervision of emergency medical staff at a fully-equipped emergency hospital. Lemtrada's side effects are profound and can cause immediate death. Lemtrada is responsible for causing many insidious side effects, one of which is autoimmune complications where the body's immune defense mechanisms attack its vital internal organs. Lemtrada also reduces the red blood cell count making blood clotting more difficult. Patients that are taking Lemtrada should watch side effects like easy bruising and cutting, wounds that will not heal, coughing up blood, and "heavier menstrual periods than normal; bleeding from your gums or nose that is new or takes longer than usual to stop; small, scattered spots on your skin that are red, pink, or purple," according to Sanofi Genzyme.

Lemtrada patients are warned the drug causes anti-glomerular basement membrane disease (AGBMD). AGBMD can lead to severe kidney disease and death. Signs of AGBMD are "swelling of the legs or feet; blood in the urine (red or tea-colored urine); decrease in urine; fatigue, and coughing up blood." Heart attack and strokes resulting in death have also been reported immediately upon taking Lemtrada and up to 72 hours afterward.

Lemtrada is a highly restricted treatment for RRMS and precautions need to be taken. Potential Lemtrada patients need to be checked for pre-existing conditions. One of the most important criteria to measure before taking Lemtrada is the patient's kidney and liver functions before treatments begin. Lemtrada patients should self-monitor for months after treatment for chest pains, breathing difficulty, lung bleeding, drooping face, prolonged headaches, yellowing of the whites of the eyes, nails, and skin, and darkened urine, according to the company.

Many RRMS sufferers and their loved ones hold Sanofi Genzyme, a French pharmaceutical company, responsible for failing to warn them of the dangers of having a stroke or heart attack immediately after taking the drug. Lemtrada was granted FDA approval in 2014, and it was not until 2018 that a stroke and arterial dissection warning from were added to Lemtrada's Black Box warning. If you or a loved one have suffered from arterial dissection or stroke from Lemtrada you should speak with a Lemtrada Stroke Lawyer to see if you qualify to file a claim.

More Recent Lemtrada Stroke Lawsuit News:

No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.